• Bionano CEO and president Dr. Erik Holmlin will participate with Dr. Bruce Korf, president of the ACMG Foundation, in the foundation’s educational and clinical laboratory genetics and genomics (LGG) awards ceremony by presenting the fellowship awards sponsored by Bionano
• A scientific session on innovations in genomics will include Dr. Ravindra Kolhe from Augusta University delivering a presentation on the use of optical genome mapping (OGM) for the detection of structural variants (SVs) in constitutional and somatic disorders
• A sponsored session will feature Dr. Brynn Levy from Columbia University presenting findings from large multi-site studies comparing OGM to traditional cytogenetic methods for prenatal and postnatal genetic analysis, and Drs. Roger Stevenson and Nikhil Sahajpal from Greenwood Genetic Center delivering a presentation on OGM’s ability to detect pathogenic variants relevant to rare disease including fragile X syndrome
• Seven scientific posters featuring results from OGM applications in rare disease, postnatal applications and genetic disorders will be presented at the conference

SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation in the American College of Medical Genetics and Genomics (ACMG) Annual Meeting 2023 with a broad range of content covering optical genome mapping’s (OGM) utility for research areas including rare genetic disease and constitutional disorders. ACMG’s Annual Meeting brings together industry, medical, and academic professionals to discuss advances in clinical genetics research. The ACMG conference will be held March 14-18, 2023, in Salt Lake City, Utah.

Bionano president and chief executive officer Dr. Erik Holmlin will participate in the conference’s opening plenary and awards ceremony, where the ACMG Foundation’s laboratory genetics and genomics (LGG) awards will be presented with Dr. Bruce Korf, president of the ACMG Foundation. The ceremony begins at 8:00 a.m. mountain time on March 15^th, 2023.

As part of a scientific session on innovations in genomics to be held on March 16th, Dr. Ravindra Kolhe from Augusta University will present on OGM’s utility for the detection of structural variants (SVs) in constitutional and somatic disorders as an alternative to traditional cytogenetic methods.

Three leaders in clinical research will participate in a sponsored session highlighting the use of OGM in prenatal and postnatal genetic analysis. Dr. Brynn Levy of Columbia University will present findings from two comprehensive multi-site studies comparing OGM to traditional cytogenetic methods for prenatal and postnatal analysis. Drs. Roger Stevenson and Nikhil Sahajpal from Greenwood Genetic Center will discuss their findings on OGM’s ability to detect pathogenic variants relevant to rare genetic disorders, including fragile X syndrome.

All scientific posters will be presented in Exhibit Hall BCD. Poster presentations and scientific workshop sessions on OGM include:

Erik Holmlin, president and chief executive officer of Bionano, added, “Improving the lives of patients and their families who are impacted by genetic disease is at the core of our purpose to elevate the health and wellness of all people. ACMG and its foundation are vehicles through which we believe we can facilitate that transformation. We are delighted to sponsor the ACMG Foundation LGG awards in their educational efforts to support the next generation of leaders in the medical genetics and genomics community. We are proud to see the broad range of posters and presentations on OGM at ACMG this year. Researchers and scientists continue to push forward conducting cutting-edge research in the human genetics space and we are pleased to see them share their findings with the ACMG community.”

More details on the conference can be found here.

About Bionano Genomics

Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com

Bionano’s OGM products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “will,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, OGM’s utility for genetic disease research in the areas reported in the presentations given and the posters made available at ACMG’s Annual Meeting, and the growth and adoption of OGM. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: global and macroeconomic events, such as the impact of the COVID-19 pandemic and the ongoing Ukraine-Russian conflict and related sanctions, on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of OGM to prove useful for research in areas including rare genetic diseases, constitutional disorders, prenatal and postnatal genetic analysis; failure of laboratories to adopt OGM; the ability of our OGM solutions to offer the anticipated benefits for and contributions to the areas reported in the presentations given and posters made available at the ACMG’s Annual Meeting; future study results contradicting the results reported in the presentations given and posters made available at the ACMG’s Annual Meeting; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2022 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
This email address is being protected from spambots. You need JavaScript enabled to view it.

Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
This email address is being protected from spambots. You need JavaScript enabled to view it.